NCT06398977 Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients
| NCT ID | NCT06398977 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sichuan Academy of Medical Sciences |
| Condition | Peritoneal Dialysis Complication |
| Study Type | INTERVENTIONAL |
| Enrollment | 70 participants |
| Start Date | 2024-03-11 |
| Primary Completion | 2026-06-30 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This study aims to explore the role of dagliflozin in preserving the residual renal function(RRF) in peritoneal dialysis (PD) patients.
Eligibility Criteria
Inclusion Criteria: * Patients with PD duration between 1 month and 3 months. * Patients aged between 18 and 75 years. * Voluntary signing of informed consent. * Stable use of a maximum tolerated dose of RAAS inhibitors for one month if hypertension is present. * Daily urine output ≥ 400ml/day. * Stable PD prescription for one month. Exclusion Criteria: * Pregnant and lactating women. * Patients with type 1 diabetes mellitus. * Patients with type 2 diabetes mellitus who have experienced diabetic ketoacidosis in the past. * Patients with chronic liver disease, including non-alcoholic fatty liver disease, cirrhosis, ALT \> 120 IU/L, and other clinically confirmed severe liver diseases. * Patients with more than 2 episodes of urinary tract infection in the past six months. * Patients with severe allergic reactions (rash or angioedema) to Dapagliflozin. * Patients using the following medications: rifampicin, phenytoin. * Patients with malignant tumors. * Patients who developed peritonitis